France
Oncodesign Services is a leading Contract Research Organization (CRO) specializing in drug discovery and preclinical services. Founded in 1995, the company is dedicated to contributing to the discovery of innovative therapies, particularly in oncology, inflammation, and infectious diseases. Offering a comprehensive range of services in medicinal chemistry, DMPK, pharmaco-imaging, bioanalysis, and in vivo/in vitro pharmacology, Oncodesign supports the R&D programs of global customers, including pharmaceutical companies, biotechs, and public research institutions.
With a mission to minimize timelines from bench to bedside, Oncodesign is a pioneer in translational medicine, aiming to evaluate the efficacy of treatments and offer innovative science. The company has established itself as a leader in creating new technological pathways to find and select the best drug candidates. With BSL1, BSL2, and BSL3 laboratories and full AAALAC international accreditation for its animal care and use program, Oncodesign maintains high standards in its facilities.
Headquartered in France, with additional operations in the United Kingdom, Germany, Canada, and the United States, Oncodesign benefits from 15,000m² of fully equipped chemistry and biologic laboratories. Notably, the company secured a €22.00M Private Equity Round investment on 23 January 2024, with backing from investors Euazeo and Edmond de Rothschild Private Equity.
Oncodesign Services is at the forefront of advancing drug discovery and preclinical services, positioning itself as a key player in the biotechnology industry and a promising investment opportunity for stakeholders in the healthcare and life sciences sectors.
